STOCK TITAN

Seagen Inc - sgen STOCK NEWS

Welcome to our dedicated news page for Seagen (Ticker: sgen), a resource for investors and traders seeking the latest updates and insights on Seagen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seagen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seagen's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
-
-
-
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
Seagen Inc

Nasdaq:SGEN

SGEN Rankings

SGEN Stock Data

43.15B
129.83M
0.81%
88.83%
5.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Bothell

About SGEN

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys